MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

161 / 348 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9. apr 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9. apr 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9. apr 2026, 23:14 UTC

Market Talk

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9. apr 2026, 23:14 UTC

Market Talk

Global Equities Roundup: Market Talk

9. apr 2026, 23:07 UTC

Market Talk

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9. apr 2026, 22:54 UTC

Market Talk

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9. apr 2026, 22:31 UTC

Uudisväärsed sündmused

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9. apr 2026, 22:31 UTC

Uudisväärsed sündmused

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9. apr 2026, 20:57 UTC

Uudisväärsed sündmused

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9. apr 2026, 20:55 UTC

Tulu

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9. apr 2026, 20:55 UTC

Tulu

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9. apr 2026, 20:55 UTC

Tulu

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. apr 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9. apr 2026, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Rowan Digital Infrastructure Announces Strategic Recapitalization

9. apr 2026, 20:25 UTC

Omandamised, ülevõtmised, äriostud

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. apr 2026, 19:30 UTC

Uudisväärsed sündmused

How Digital Currencies Have Helped Iran -- WSJ

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

161 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.